INTRODUCTION AND AIMS:
Chronic heart failure (HF) leads to the development of a chronic cardio-renal syndrome. Cardiac resynchronization therapy (CRT) improves the heart function of patients with HF and consequently should improve the function of the kidneys. At the same time, CRT implantation itself, with the use of a contrast agent, can lead to contrast induced nephropathy (CIN) . The aim of the study was to assess the effect of CRT implantation on renal function within the first 48 hours after the procedure. METHODS: Currently a prospective interventional study includes 48 patients with a mean age of 67.869.6 years, 37(77,1%) men and 11 (22.9%) females, with HF in the NYHA classes: II (n¼21; 43.75%), III (n¼24; 50%), IV (n¼3; 6.25%), and the average of ejection fraction 2466.9%. In analyzed group specified co-morbid conditions were observed: arterial hypertension (n¼38; 79.2%), diabetes mellitus type 2 (n¼24; 50%), ischemic heart disease (n¼ 28; 58,3%), atrial fibrillation (n ¼ 22; 45.8%). During CRT implantation a non-ionic contrast agent (aqueous solution of jomeprol; osmolality of 726634 mOsm/kg of water) with an average dose of 72.2644.9 ml was administered. Patients initially met the criteria of chronic kidney disease (CKD) by KDIGO 2012 at stages: G1 n¼6 (12.5%), G2 n¼25 (52.1%), G3 n¼16 (33.3%), G4 n¼1 (2, 1%) and A1 n¼35 (72.9%); A2 n¼12 (25%); A3 n¼1 (2.1%). Urine samples were undertaken at morning, before the procedure and then 48 hours after implantation. Following parameters were examined: albumin, neutrophils gelatinase-associated protein (uNGAL), creatinine. Based on them, urine albumin-creatinine ratio (uACR; mg/g) and the uNGAL to creatinine ratio (uNCR; ug/g) were calculated. At the same time, serum creatinine concentration was performed and eGFR CKD-EPI (ml/min/1.73m
2 ) was calculated. RESULTS: On admission, in the study group the average of renal function biomarkers were: eGFR¼67. 5619.8; uACR¼89.46151.8; uNCR¼48.96130 . At 48 hours after CRT implantation, eGFR was found to be insignificant lower (63.6621.1; p¼0.46) than before CRT implantation in all population. After the procedure in 25 (52.1%) patients with CKD G2 only, the eGFR decreased by an average of 8.1 -from 74.2616.9 to 66.16 7.7 (p¼0.02). In addition, a statistically significant decline in uACR (50.4695; p¼0.0003) after CRT implantation was observed in the whole group. There were no statistically significant changes in uNCR (38.66109.2; p ¼ 0.37) after 48 hours from procedure. CONCLUSIONS: The CRT implantation, performed in patients with HF is not a risk factor for CIN, as evidenced by the lack of uNCR growth in the whole study group and stable glomerular filtration especially in patients with CKD G3-G4 after the first 48 hours after procedure. Moreover, is clinically relevant for cardiovascular complications and the CKD progresion prevention, thath reduction of albuminuria was evaluated instantly on the second day after the procedure 
Bardoxolone methyl (BARD) promotes resolution of inflammation by inducing Nrf2 and suppressing NF-kB. Treatment with bardoxolone methyl in a phase 2 study (BEAM) and a subsequent phase 3 study (BEACON) in patients with type 2 diabetes and chronic kidney disease (CKD) resulted in increases in estimated glomerular filtration rate (eGFR) as well as urinary albumin-to-creatinine ratio (UACR). Additional post-hoc analyses were performed to further understand the relationship between urinary albumin excretion and eGFR with BARD in CKD patients.
METHODS:
Patients in BEAM (n¼227) were randomized 1:1:1:1 to oral placebo or bardoxolone methyl (25, 75, or 150 mg of crystalline formulation) for 52 weeks. Patients in BEACON (n¼2185) were randomized 1:1 to placebo or bardoxolone methyl (20 mg of amorphous spray-dried dispersion formulation). A longitudinal model was used to compare log UACR/eGFR changes in BARD versus placebo groups in BEAM and BEACON. RESULTS: Initial UACR increases in BEAM and BEACON were attenuated after 6 months in bardoxolone methyl-treated patients. The increases in UACR were significantly correlated with increases in eGFR in both studies. Furthermore, overall changes in log UACR/eGFR ratios with BARD were lower than placebo (least-squared means: -0.017 and -0.024 versus placebo in BEAM and BEACON, respectively), suggesting that when adjusted for eGFR changes, bardoxolone methyl may reduce albumin excretion relative to placebo. CONCLUSIONS: Conclusions: The profile of proteinuria increases with bardoxolone methyl treatment is distinct from those associated with the progression of CKD. Instead, the transient increases in urinary albumin excretion are likely due to increases in filtration and decreased tubular albumin absorption. 
FP153 RENAL FUNCTION EVALUATION AFTER CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION

METHODS:
The investigation included 59 patients with advanced heart failure undergoing CFLVADI as bridge to transplantation: age 50.4613.1 years. Glomerular filtration rate (GFR) was calculated by CKD-EPI 2011 formula. Patients were categorized into 2 groups according to pre-implantation GFR level: 1-with irreversible GFR impairment (GFR &#8804; 60 ml/min/1.73m 2 , n ¼ 7), 2 -GFR ! 60 ml/min/1.73m 2 , n ¼ 52). Post-operative acute injury cases were excluded from both groups. 1 grouppre-LVAD GFR Median -54 (25 %'s-75 %'s -33-59), 2 group -pre-LVAD GFR . RESULTS: Significant difference wasn't found between post-LVAD GFR for group 1 at 1, 6, 12 months: 52 (25 %'s-75 %'s -37-59), 58 (25 %'s-75 %'s -52-94), 58 (25 %'s-75 %'s -47-100) respectively, Friedman ANOVA Chi Sqr.¼1.5, p¼0.68. LVAD GFR for group 2 at 1, 6, 12 months: 100.5 (25 %'s-75 %'s -83.5-110.5), 94 (25 %'s-75 %'s -78-112), 91.5 (25 %'s-75 %'s -70-110) respectively. Friedman ANOVA analysis revealed significant differences in post-LVAD GFR dynamics: Chi Sqr ¼ 8.18, p¼0.04. Post-LVAD GFR medians were staying in normal ranges, but slightly decreased by every time point. Post hoc analysis (Wilcoxon matched pairs test with Bonferroni correction for p>0.01, did not approve significant changes for this group probably because of small difference in values. CONCLUSIONS: This study didn't reveal significant changes in kidney function dynamics after CFLVADI in both groups. LVAD continuous flow presumptive negative effect on the renal blood flow was not confirmed. Consequently, within a year in case of adequate compliance, chronic kidney disease will not progress in these patients. More observations are needed to clarify effect of CFLVADI on kidney function to determine terms of timely implantation, isolate CKD risk groups and plan for heart-kidney transplantation. 
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